Latest Regulatory Filings News

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

HALO Technologies reports solid quarterly revenue growth and nears completion of a $6.75 million capital raise, while progressing its UK wealth management platform launch and preparing to introduce Managed Funds in Australia.

NT Minerals Limited reported a cautious cash flow profile for the March 2025 quarter, with operating outflows offset by strategic financing, securing liquidity for the foreseeable future.

Bridge SaaS Limited reports a 7% increase in NDIS participant numbers through its majority-owned Brightside, while advancing regional expansion and targeting cash flow positivity by refining operational efficiencies.

XPON Technologies reported a modest 1% quarter-on-quarter revenue increase to $2.09 million in Q3 FY25, driven by a strong 87% recurring revenue base and a 75% gross margin. The company extended its convertible note maturity and is focused on recalibrating sales and accelerating AI innovation.

Accent Resources NL reported a solid cash position of A$14 million at the end of Q1 2025, supported by prudent financing and controlled expenditure. The company’s quarterly cash flow highlights its ongoing commitment to exploration while maintaining financial stability.

AVADA Group Limited reported a seasonally subdued quarter ending March 2025 but achieved positive operating cash flow through disciplined cost reductions and operational efficiencies. A strategic review of its New Zealand operations is underway amid challenging market conditions.

AssetOwl Ltd reports a cautious quarter marked by debt renegotiations with related parties, board changes, and a tight cash position as it seeks to revive shareholder value.

TZ Limited reported a challenging Q3 FY2025 with a $1.03 million net cash outflow amid US tariff disruptions but strengthened its SaaS base through the Keyvision acquisition, positioning for a rebound and growth in FY2026.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.

Altair Minerals has made a significant leap with the acquisition of the Venatica Copper Project in Peru, revealing multiple high-grade porphyry systems that could position the company as a key player in a globally significant copper belt.